Viral latency and potential eradication of HIV-1

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 8, 2012, Pages 855-857

  Matreyek, Kenneth A ^a   Oztop, Ilker ^a   Freed, Eric O ^b   Engelman, Alan ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

HAART; HIV 1 activation; HIV 1 replication; HIV AIDS; viral latency

Indexed keywords

VIRUS DNA;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE SYSTEM; LYMPHOCYTE SUBPOPULATION; MEMORY T LYMPHOCYTE; NONHUMAN; PROVIRUS; REVIEW; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARRIER STATE; CD4-POSITIVE T-LYMPHOCYTES; HISTONE DEACETYLASE INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MODELS, ANIMAL; PROVIRUSES; TREATMENT OUTCOME; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84867092174     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.68     Document Type: Review

References (20)

1. Jilek BL, Zarr M, Sampah ME et al. A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat. Med. 18(3), 446-451 (2012).
2. Chun TW, Justement JS, Murray D et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 24(18), 2803-2808 (2010).
3. Joos B, Fischer M, Kuster H et al.; Swiss HIV Cohort Study. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc. Natl Acad. Sci. USA 105(43), 16725-16730 (2008).
4. Sedaghat AR, Siliciano RF, Wilke CO. Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect. Dis. 8, 2 (2008).
5. Palmer S, Maldarelli F, Wiegand A et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl Acad. Sci. USA 105(10), 3879-3884 (2008).
6. Perelson AS, Essunger P, Cao Y et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387(6629), 188-191 (1997).
7. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271(5255), 1582-1586 (1996).
8. Chun TW, Carruth L, Finzi D et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387(6629), 183-188 (1997).
9. Chomont N, El-Far M, Ancuta P et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15(8), 893-900 (2009).
10. Eckstein DA, Penn ML, Korin YD et al. HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. Immunity 15(4), 671-682 (2001).
11. Buzón MJ, Massanella M, Llibre JM et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat. Med. 16(4), 460-465 (2010).
12. Margolis DM. Histone deacetylase inhibitors and HIV latency. Curr. Opin. HIV AIDS 6(1), 25-29 (2011).
13. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 25(2), 207-212 (2009).
14. Miller-Jensen K, Dey SS, Pham N, Foley JE, Arkin AP, Schaffer DV. Chromatin accessibility at the HIV LTR promoter sets a threshold for NF-kB mediated viral gene expression. Integr. Biol. (Cam.) 4(6), 661-671 (2012).
15. Denton PW, Krisko JF, Powell DA et al. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS ONE 5(1), e8829 (2010).
16. Denton PW, Olesen R, Choudhary SK et al. Generation of HIV latency in humanized BLT mice. J. Virol. 86(1), 630-634 (2012).
17. Ling B, Mohan M, Lackner AA et al. The large intestine as a major reservoir for simian immunodeficiency virus in macaques with long-term, nonprogressing infection. J. Infect. Dis. 202(12), 1846-1854 (2010).
18. Kearney M, Spindler J, Shao W et al. Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy. J. Virol. 85(2), 1067-1076 (2011).
19. Shan L, Deng K, Shroff NS et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36(3), 491-501 (2012).
20. Wu X, Zhou T, Zhu J et al.; NISC Comparative Sequencing Program. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333(6049), 1593-1602 (2011).